Product Information
ULORIC 40 MG TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $10.5440 per EA under NDC 64764091830. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Feb 13, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the febuxostat market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
64764091830
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FEBUXOSTATApproval Type
New Drug (NDA)
FDA Application
NDA021856FDA Approved
2/13/2009
TE Code
AB
On Market Since
2/13/2009
Pharmacological Classes
Price Statistics
The NADAC for ULORIC 40 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 59.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.5440 per EA |
|---|---|
| All-time high | $10.6068 (Jun 16, 2021) |
| All-time low | $6.5931 (Nov 28, 2013) |
| 52-week high | $10.5817 |
| 52-week low | $10.5313 |
| Median price | $10.5244 |
| Average price | $9.8564 |
| Largest weekly change | +9.9% (Apr 15, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
febuxostat market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Xanthine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ULORIC 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ULORIC 40 MG TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $10.5440 per EA (NDC 64764091830), effective Sep 30, 2026.
How has the price of ULORIC 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for ULORIC 40 MG TABLET has risen 59.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ULORIC 40 MG TABLET?
Since Nov 28, 2013, the NADAC for ULORIC 40 MG TABLET has ranged from a low of $6.5931 (Nov 28, 2013) to a high of $10.6068 (Jun 16, 2021), with a median of $10.5244 per EA.
Are there cheaper alternatives to ULORIC 40 MG TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FEBUXOSTAT 40 MG TABLET, is $0.1911 per EA — about 98% below ULORIC 40 MG TABLET.
Who manufactures ULORIC 40 MG TABLET?
ULORIC 40 MG TABLET (NDC 64764091830) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.